Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2010 Oct 21;5(10):e13490.
doi: 10.1371/journal.pone.0013490.

Plasmodium falciparum malaria challenge by the bite of aseptic Anopheles stephensi mosquitoes: results of a randomized infectivity trial

Affiliations
Randomized Controlled Trial

Plasmodium falciparum malaria challenge by the bite of aseptic Anopheles stephensi mosquitoes: results of a randomized infectivity trial

Kirsten E Lyke et al. PLoS One. .

Abstract

Background: Experimental infection of malaria-naïve volunteers by the bite of Plasmodium falciparum-infected mosquitoes is a preferred means to test the protective effect of malaria vaccines and drugs. The standard model relies on the bite of five infected mosquitoes to induce malaria. We examined the efficacy of malaria transmission using mosquitoes raised aseptically in compliance with current Good Manufacturing Practices (cGMPs).

Methods and findings: Eighteen adults aged 18-40 years were randomized to receive 1, 3 or 5 bites of Anopheles stephensi mosquitoes infected with the chloroquine-sensitive NF54 strain of P. falciparum. Seventeen participants developed malaria; fourteen occurring on Day 11. The mean prepatent period was 10.9 days (9-12 days). The geometric mean parasitemia was 15.7 parasites/µL (range: 4-70) by microscopy. Polymerase chain reaction (PCR) detected parasites 3.1 (range: 0-4) days prior to microscopy. The geometric mean sporozoite load was 16,753 sporozoites per infected mosquito (range: 1,000-57,500). A 1-bite participant withdrew from the study on Day 13 post-challenge and was PCR and smear negative.

Conclusions: The use of aseptic, cGMP-compliant P. falciparum-infected mosquitoes is safe, is associated with a precise prepatent period compared to the standard model and appears more efficient than the standard approach, as it led to infection in 100% (6/6) of volunteers exposed to three mosquito bites and 83% (5/6) of volunteers exposed to one mosquito bite.

Trial registration: ClinicalTrials.gov NCT00744133.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: PFB, AR,ML, SC, BKLS, and SLH are employees of Sanaria, Inc. and/or Protein Potential, LLC representing the sponsors of the study and participated in development of study design, data collection and analysis, publication decisions and manuscript publication. The funding sponsor, however, was NIAID/DMID/VTEU and members of this organization played no role in the development of the manuscript or publication. These affiliations do not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials.

Figures

Figure 1
Figure 1. Study flow diagram.
Figure 2
Figure 2. Time to infection of volunteers measured by blood smear and PCR.
The time to infection of all volunteers (pooled exposed to 1, 3 and 5 infectious bites) measured by blood smear (solid line, median time to infection  = 11 days) and PCR (dashed line, median time to infection  = 8 days) was significantly different (p≤0.001, Mantel-Cox test).
Figure 3
Figure 3. Dynamics of parasite growth in volunteers after challenge.
Each line shows the parasite density in an individual volunteer as measured by PCR after being bitten by 1 (top), 3 (middle) or 5 (bottom) Plasmodium falciparum-infected Anopheles stephensi mosquitoes. All volunteers were treated on day 11 (vertical dashed line on each panel) when parasites were detected by blood smear, except for one volunteer in the 1 bite group (blue dashed line) who was positive and treated on day 12, one volunteer (grey dashed line) in the 3 bite group who was positive and treated on day 10, and one volunteer (red dashed line) in the 5 bite group who was positive and treated on day 9. Data are presented until last positive identification of parasites in the blood by PCR. Values shown as 1 on the log scale were negative.

References

    1. Driver JR, Gammel JA, Darnosh LJ. Malaria treatment central nervous system “syphilis”. 1926. Journal of the American Medical Association (lxxxvii), 1921, Cited in Bunker ‘Recent treatment of general paralysis’-
    1. Brown EM. Why Wagner-Juaregg won the Nobel Prize for discovering Malaria Therapy for General Paresis of the Insane. Journal of Psychiatry. 2000;xi:371–382.
    1. Malaria 2010: more ambition and accountability please. Lancet. 2010;375:1407-. - PubMed
    1. Epstein JE, Rao S, Williams F, Freilich D, Luke T, et al. Safety and clinical outcome of experimental challenge of human volunteers with Plasmodium falciparum-infected mosquitoes: an update. J Infect Dis. 2007;196:145–154. - PubMed
    1. Moorthy VS, Diggs C, Ferro S, Good MF, Herrera S, et al. Report of a consultation on the optimization of clinical challenge trials for evaluation of candidate blood stage malaria vaccines, 18-19 March 2009, Bethesda, MD, USA. Vaccine. 2009;27:5719–5725. - PubMed

Publication types

Associated data